GO Main Menu Go Main Contents Go Bottom Menu

CelltrionHealthcare

gnb show

MENU

Gnb close

Press Release

VEGZELMA® (bevacizumab-adcd) receives preferred formulary status with Ventegra® for commercially insured patients VEGZELMA® (bevacizumab-adcd) receives preferred formulary status with Ventegra® for commercially insured patients 2023-12-11

VEGZELMA® (bevacizumab-adcd) receives preferred formulary status with Ventegra® for commercially insured patients   Ventegra® will list VEGZELMA®(bevacizumab-adcd) on its national formulary that serves more than 400 clients and more than 13 million members and patients in the U.S. Celltrion USA completes a contract ...

Celltrion USA announces distribution and incorporation of YUFLYMA® (adalimumab-aaty), a Humira® biosimilar, to CarePartners Specialty Pharmacy Cost Savings Programs Celltrion USA announces distribution and incorporation of YUFLYMA® (adalimumab-aaty), a Humira® biosimilar, to CarePartners Specialty Pharmacy Cost Savings Programs 2023-10-26

Celltrion USA announces distribution and incorporation of YUFLYMA® (adalimumab-aaty), a Humira® biosimilar, to CarePartners Specialty Pharmacy Cost Savings Programs YUFLYMA® (adalimumab-aaty) was first approved by the Food and Drug Administration on May ...

Celltrion USA Announces U.S. FDA Approval of ZYMFENTRA™ (infliximab-dyyb), the First and Only Subcutaneous infliximab, for the Treatment of People With Inflammatory Bowel Disease Celltrion USA Announces U.S. FDA Approval of ZYMFENTRA™ (infliximab-dyyb), the First and Only Subcutaneous infliximab, for the Treatment of People With Inflammatory Bowel Disease 2023-10-23

Celltrion USA Announces U.S. FDA Approval of ZYMFENTRA™ (infliximab-dyyb), the First and Only Subcutaneous infliximab, for the Treatment of People With Inflammatory Bowel Disease ZYMFENTRA™ is the first and only FDA-approved subcutaneous (SC) formulation of i...

게시물 검색
  • 45
    Celltrion accelerates development of COVID-19 anti..
    Celltrion accelerates development of COVID-19 antiviral treatment and aims to launch rapid self-testing kit Celltrion completes first step of developing an antiviral treatment to fight COVID-19 and hopes to begin human clinical trials in the …
    2020-03-23
  • 44
    Celltrion Healthcare showcases positive 1-year res..
    Celltrion Healthcare showcases positive 1-year results for novel subcutaneous formulation of infliximab in patients with active Crohn’s disease and ulcerative colitis presented at The European Crohn's and Colitis Organisation (ECCO) annual congress…
    2020-02-14
  • 43
    ‘First Mover to Game Changer’: Celltrion announces..
    ‘FirstMover to Game Changer’: Celltrion announces 2020-2030 strategy at the 38thJ.P. Morgan Healthcare Conference ·Celltrion’s Chairman JungJin Seo announced the company’s strategy for the upcoming decade including itsbiosimilar, bioinnovative …
    2020-01-16
  • 42
    Celltrion Healthcare receives EU marketing authori..
    Celltrion Healthcare receives EU marketing authorisation forworld’s first subcutaneous formulation of infliximab, Remsima SC™, for thetreatment of people with rheumatoid arthritis ·Remsima SC™ is thesubcutaneous version of Celltrion Healthcare’s…
    2019-11-26
  • 41
    New data show non-inferiority of efficacy for subc..
    New data show non-inferiority of efficacy for subcutaneous formulation of CT-P13 (biosimilar infliximab) to intravenous formulation of CT-P13 in people with rheumatoid arthritis · The results after switching from intravenous (IV) to subcutan…
    2019-11-09
  • 40
    New subcutaneous formulation of Celltrion Healthca..
    New subcutaneousformulation of Celltrion Healthcare’s CT-P13 (biosimilar infliximab) showspositive Phase 1 results for the treatment of IBD in data presented at UEGWeek Barcelona 2019 · Results from a multicentre, open-label, randomised Phase 1, p…
    2019-10-18
  • 39
    Celltrion Healthcare receives CHMP positive opinio..
    Celltrion Healthcare receives CHMP positive opinion for novel subcutaneous formulation of CT-P13 (biosimilar infliximab) for the treatment of people with rheumatoid arthritis CT-P13 subcutaneous (SC) (biosimilar infliximab) recommended by CHMP…
    2019-09-22
  • 38
    New Subcutaneous Formulation of Celltrion Healthca..
    Data at 54 weeks showed that the subcutaneous (SC) formulation of CT-P13 was comparable in terms of the efficacy and safety when investigated against intravenous (IV) formulation of CT-P13 (biosimilar infliximab) in rheumatoid arthritis (RA). •The…
    2019-06-12
  • 37
    Celltrion Healthcare showcases initial data from y..
    The subcutaneous (SC) formulation of CT-P13 was comparable in terms of efficacy and safety with intravenous (IV) formulation for the treatment of Crohn’s disease up until week 54, indicating that CT-P13 SC could be a future alternative in…
    2019-03-08
  • 36
    [Notice to shareholders] Celltrion Healthcare’s St..
    [Notice to shareholders] Celltrion Healthcare’s Statement on press release from YTN The following is an official response by Celltrion Healthcare to the press release from YTN titled “The Financial Supervisory Services(FSS) investigation at Celltr…
    2018-12-11